Opinion|Videos|November 27, 2024
Navigating Healthcare Access and Decision-Making
Key Takeaways
- Integrating HER2-directed therapies into NSCLC treatment requires alignment with existing protocols and timely updates to decision-making processes.
- Establishing frameworks for rapid incorporation of emerging therapies and fostering adaptive decision-making processes are essential strategies.
An analysis of challenges and strategies for integrating HER2-directed therapies into decision-making for NSCLC, with a focus on timely updates, collaborative efforts among stakeholders, and balancing equitable access with cost management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key challenges in integrating HER2-directed therapies into existing internal decision-making processes for NSCLC?
- What strategies can be employed to ensure timely updates to internal decision-making processes as new HER2-directed therapies emerge?
- How can collaboration between payers, providers, and manufacturers be leveraged to ensure equitable access to HER2-directed therapies while managing costs?
Advertisement
Related to this article
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.
UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.
At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
Advertisement
Advertisement
Trending on AJMC
1
At the Pharmacy, Affordability Connects Policy, Plans, and Patients
2
Olanzapine/Samidorphan Tied to Longer Persistence in Schizophrenia
3
Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial
4
UAB Works to Deliver Cutting-Edge Cancer Therapies, Reach Every Patient
5